Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 34528187)

  • 1. Furmonertinib: First Approval.
    Deeks ED
    Drugs; 2021 Oct; 81(15):1775-1780. PubMed ID: 34528187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study.
    Shi Y; Hu X; Zhang S; Lv D; Wu L; Yu Q; Zhang Y; Liu L; Wang X; Cheng Y; Ma Z; Niu H; Wang D; Feng J; Huang C; Liu C; Zhao H; Li J; Zhang X; Jiang Y; Gu C
    Lancet Respir Med; 2021 Aug; 9(8):829-839. PubMed ID: 33780662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study.
    Shi Y; Chen G; Wang X; Liu Y; Wu L; Hao Y; Liu C; Zhu S; Zhang X; Li Y; Liu J; Cao L; Cheng Y; Zhao H; Zhang S; Zang A; Cui J; Feng J; Yang N; Liu F; Jiang Y; Gu C;
    Lancet Respir Med; 2022 Nov; 10(11):1019-1028. PubMed ID: 35662408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lazertinib: First Approval.
    Dhillon S
    Drugs; 2021 Jun; 81(9):1107-1113. PubMed ID: 34028784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First report of furmonertinib as a first-line treatment in advanced lung adenocarcinoma patients harboring EGFR exon 20 insertion mutations after the kinase domain αC-helix: Two case reports and a literature review.
    Han H; Zhang X; Liu X; Zhao J; Zhang J; Zhang J; Zhu H; Jiao S; Tang H
    Medicine (Baltimore); 2023 Dec; 102(52):e36667. PubMed ID: 38206746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [First-line Treatment with Furmonertinib Mesylate in Lung Adenocarcinoma Patient 
with EGFR Exon 20 Insertion Mutantion].
    Li Z; Wei T; Zeng D; Zhao L; Zhang J; Chen L
    Zhongguo Fei Ai Za Zhi; 2024 Mar; 27(3):241-244. PubMed ID: 38590198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A real-world study of the efficacy and safety of furmonertinib for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations.
    Sa H; Shi Y; Ding C; Ma K
    J Cancer Res Clin Oncol; 2023 Aug; 149(10):7729-7742. PubMed ID: 37004599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Central nervous system efficacy of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small cell lung cancer: a pooled analysis from two phase 2 studies.
    Hu X; Zhang S; Ma Z; Feng J; Wu L; Lv D; Zhou J; Zhang X; Liu L; Yu Q; Liao W; Zhang Y; Wang X; Cheng Y; Niu H; Wang Z; Wang D; Huang C; Liu C; Zhao H; Feng J; Li J; Ying K; Yang N; Qin S; Hu J; Liu F; Jiang Y; Ge N; Shi Y
    BMC Med; 2023 Apr; 21(1):164. PubMed ID: 37118803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Befotertinib: First Approval.
    Blair HA
    Drugs; 2023 Oct; 83(15):1433-1437. PubMed ID: 37751131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of re-challenging 160 mg furmonertinib for advanced NSCLC after resistance to third-generation EGFR-TKIs targeted agents: A real-world study.
    Qi R; Fu X; Yu Y; Xu H; Shen M; He S; Lv D
    Lung Cancer; 2023 Oct; 184():107346. PubMed ID: 37604026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: Similarities and Differences.
    Chen L; Zhou Y; Gan C; Wang X; Liu Y; Dong C; He R; Yang J
    Cancer Invest; 2022 Aug; 40(7):590-603. PubMed ID: 35445633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors.
    Nadler E; Pavilack M; Espirito JL; Clark J; Fernandes A
    Adv Ther; 2020 Feb; 37(2):946-954. PubMed ID: 31955357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial.
    Zhang YC; Chen ZH; Zhang XC; Xu CR; Yan HH; Xie Z; Chuai SK; Ye JY; Han-Zhang H; Zhang Z; Bai XY; Su J; Gan B; Yang JJ; Li WF; Tang W; Luo FR; Xu X; Wu YL; Zhou Q
    EBioMedicine; 2019 May; 43():180-187. PubMed ID: 31027916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Olmutinib: First Global Approval.
    Kim ES
    Drugs; 2016 Jul; 76(11):1153-7. PubMed ID: 27357069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful salvage therapy using high-dose furmonertinib (AST2818) for non-small-cell lung cancer after Osimertinib resistance: a case report.
    Cheng D; Tang S; Li D; Zhao W; Wei W; Fang C; Ji M
    Anticancer Drugs; 2022 Sep; 33(8):768-772. PubMed ID: 35946524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An evaluation of aumolertinib for the treatment of EGFR T790M mutation-positive non-small cell lung cancer.
    Wang J; Wu L
    Expert Opin Pharmacother; 2022 Apr; 23(6):647-652. PubMed ID: 35272542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mobocertinib: Mechanism of action, clinical, and translational science.
    Hanley MJ; Camidge DR; Fram RJ; Gupta N
    Clin Transl Sci; 2024 Mar; 17(3):e13766. PubMed ID: 38511563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, tolerability, and anti-tumor activity of olmutinib in non-small cell lung cancer with T790M mutation: A single arm, open label, phase 1/2 trial.
    Kim DW; Lee DH; Han JY; Lee J; Cho BC; Kang JH; Lee KH; Cho EK; Kim JS; Min YJ; Cho JY; An HJ; Kim HG; Lee KH; Kim BS; Jang IJ; Yoon S; Han O; Noh YS; Hong KY; Park K
    Lung Cancer; 2019 Sep; 135():66-72. PubMed ID: 31447004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
    Gelatti ACZ; Drilon A; Santini FC
    Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Central Nervous System Efficacy of Furmonertinib (AST2818) Versus Gefitinib as First-Line Treatment for EGFR-Mutated NSCLC: Results From the FURLONG Study.
    Shi Y; Chen G; Wang X; Liu Y; Wu L; Hao Y; Liu C; Zhu S; Zhang X; Li Y; Liu J; Cao L; Cheng Y; Zhao H; Zhang S; Zang A; Cui J; Feng J; Yang N; Liu F; Jiang Y; Gu C
    J Thorac Oncol; 2022 Nov; 17(11):1297-1305. PubMed ID: 35932953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.